Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression

British Journal of Cancer

Volumn 101, Issue 3, 2009, Pages 432-440

  Chen, H ^a,b   Hao, J ^b,c   Wang, L ^a,b   Li, Y ^b,c  

^a Henan Tumor Hospital   (China)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

CD44; Epithelial ovarian cancer; Metastasis; Multiple drug resistance proteins; UPA

Indexed keywords

HERMES ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; UROKINASE;

ADULT; AGED; ARTICLE; ASCITES; CANCER GRADING; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD44; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICROSCOPY, CONFOCAL; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 68149138779     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605185     Document Type: Article

References (38)

1. Afify AM, Craig S, Paulino AF (2006) Temporal variation in the distribution of hyaluronic acid, CD44s, and CD44v6 in the human endometrium across the menstrual cycle. Appl Immunohisto M M 14: 328-333
2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinasetype plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
3. Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Melendez-Alafort L, Mazzi U, Zanovello P, Rosato A (2008) A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 14: 3598-3606
4. Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000) Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma: diagnostic and prognostic implications. Clin Exp Metastasis 18: 197-202
5. Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN, Cuasay LC, Brunner N, Jones TR, Silverman MH, Gold MA (2005) A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 99: 50-57
6. Bhoola S, Hoskins WJ (2006) Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 107: 1399-1410
7. Borgfeldt C, Casslen B, Liu CL, Hansson S, Lecander I, Astedt B (1998) High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer 79: 588-595
8. Borgfeldt C, Hansson SR, Gustavsson B, Masback A, Casslen B (2001) Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer 92: 497-502
9. Bourguignon LY, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283: 17635-17651
10. Casslen B, Bossmar T, Lecander I, Astedt B (1994) Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer 30: 1302-1309
11. Creasman WJ (1989) Announcement, FIGO stages 1988. Revisions. Gynecol Oncol 5: 125-127
12. Cui Y, König J, Buchholz U, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugated transport mediated by the atypical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929-937
13. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163
14. Germann UA (1996) P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944
15. Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ, Guevorkian M, Edmiston M, Zhao D, Glackin CA, Kim SU, Aboody KS (2008) Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 26: 1406-1413
16. Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, Karen S, Aboody KS (2007) Identification of uPAR positive chemoresistant cells in small cell lung cancer. PLoS ONE 2: e243
17. Hadnagy A, Gaboury L, Beaulieu R, Balicki D (2006) SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312: 3701-3710
18. Kayastha S, Freedman AN, Piver MS, Mukkamalla J, Romero-Guittierez M, Werness BA (1999) Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 5: 1073-1076
19. Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M, Terao T (2002) CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells. Int J Cancer 102: 379-389
20. Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M (2001) Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 7: 1743-1749
21. Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22: 7537-7552
22. Materna V, Pleger J, Hoffmann U, Lage H (2004) RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, transand MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94: 152-160
23. Miletti-Gonzalez KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, Apolito K, Shih WJ, Hait WN, Rodriguez-Rodriguez L (2005) The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65: 6660-6667
24. Misra S, Ghatak S, Toole BP (2005) Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 280: 20310-20315
25. Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319
26. Ozalp SS, Yalcin OT, Tanir M, Kabukcuoglu S, Etiz E (2002) Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies. Eur J Gynaecol Oncol 23: 337-340
27. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller Jr AF, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98-106
28. Ross JS, Sheehan CE, William SS, Malfetano JH, Szyfelbein WM, Kallakury BV (2001) Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am J Clin Pathol 116: 122-128
29. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet Jr R, Badve S, Nakshatri H (2006) CD44+/CD24 breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59
30. Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205-222
31. Sillanpaa S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM (2003) CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res 9: 5318-5324
32. Song YJ, Qu CF, Rizvi SM, Li Y, Robertson G, Raja C, Morgenstern A, Apostolidis C, Perkins AC, Allen BJ (2006) Cytotoxicity of PAI2, C595 and herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett 234: 176-183
33. Underhill C (1992) CD44: the hyaluronan receptor. J Cell Sci 103: 293-298
34. van Herwaarden AE, Jonker JW, Wagenaar E, Brin-khuis RF, Schellens JH, Beijnen JH, Schinkel AH (2003) The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine. Cancer Res 63: 6447-6452
35. Xing H, Wang S, Weng D, Chen G, Yang X, Zhou J, Xu G, Lu Y, Ma D (2007) Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Reports 17: 117-122
36. Yeo TK, Nagy JA, Yeo KT, Dvorak HF, Toole BP (1996) Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol 148: 1733-1740
37. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y (1999) Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25: 387-394
38. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320